In a report released today, Derek Archila from Stifel Nicolaus maintained a Buy rating on Esperion (ESPR), with a price target of $50.00. The company’s shares closed last Monday at $28.99, close to its 52-week low of $24.82.
According to TipRanks.com, Archila is a 4-star analyst with an average return of 9.3% and a 46.2% success rate. Archila covers the Healthcare sector, focusing on stocks such as DBV Technologies SA – American, Madrigal Pharmaceuticals, and Phasebio Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Esperion with a $62.50 average price target.
See today’s analyst top recommended stocks >>
Based on Esperion’s latest earnings release for the quarter ending June 30, the company reported a quarterly revenue of $212 million and net profit of $125 million. In comparison, last year the company earned revenue of $982K and had a GAAP net loss of $54.22 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Esperion Therapeutics, Inc. engages in the development and commercialization of oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol. It offers NEXLETOL (bempedoic acid) tablets, and NEXLIZET (bempedoic acid and ezetimibe) tablets. The company was founded by Roger S. Newton, Hans Ageland, Jan O. Johansson, Anders Paul Wiklund, Michael E. Pape, David I. Scheer and Charles L. Bisgaier in May 1998 and is headquartered in Ann Arbor, MI.
